PRESIDENT AND FELLOWS OF HARVARD COLLEGE

• SEATTLE CHILDREN'S HOSPITAL

  UEI SZ32VTCXM799

  $573.2K

  Subcontractor to this prime · 1 sub-award · latest Sep 10, 2025

  • National Institutes of Health
  • “THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB). THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), SERUM, AND OTHER CLINICAL SAMPLES TO SCRI AND THE PHOENIX PARTNERS. NON-HUMAN PRIMATE (NHP) SAMPLES AND/OR DOWNSTREAM DATA MAY BE SHARED WITH THE PARTNERS ON THIS CONTRACT. OPTION 3 ACTIVITIES: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN THE NHP MODEL OF TB SCRI HAS WORKED WITH DR. RYAN MCNAMARA, WHO HAS PREVIOUSLY BEEN EMPLOYED AT THE RAGON INSTITUTE, TO DEVELOP A WORKPLAN FOR THE SYSTEM SEROLOGY ENDPOINTS FOR BOTH CLINICAL AND PRECLINICAL EVALUATIONS. WE HAVE CONFIRMED THAT A LIST OF 207 M.TB ANTIGENS THAT WERE RECENTLY PUBLISHED ARE NOT PROPRIETARY TO RAGON AND ARE AN APPROPRIATE SET FOR OUR INVESTIGATIONS. TASK 3.7 COMPARE IMMUNE PROFILES IN NHP, SMALL ANIMAL MODELS AND HUMANS TO IDENTIFY CORRELATES OF PROTECTION. SUBTASK 3.7.1 EVALUATE HUMORAL IMMUNITY AS A VACCINE-INDUCED CORRELATE OF PROTECTION USING SYSTEMS SEROLOGY IN THE NHP MODEL. SEVERAL EFFECTOR FUNCTIONS BASED ON THE FC PORTION OF THE ANTIBODY CAN CONTRIBUTE TO THE CLEARANCE OF ORGANISMS, INCLUDING COMPLEMENT ACTIVITY, ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS (ADCP), ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC), ANTIBODY-DEPENDENT CYTOKINE AND CHEMOKINE SECRETION. SYSTEMS SEROLOGY ANALYSIS WILL BE USED TO EVALUATE ANTIBODY EFFECTOR FUNCTIONS INCLUDING NK CELL ACTIVATION, ADCP, AND ADCC. THESE ASSAYS CAPTURE OVER 100 BIOPHYSICAL AND FUNCTIONAL CHARACTERISTICS OF POLYCLONAL ABS, INC”
• THE RAND CORPORATION

  UEI YY46Q97AEZA8

  $500K

  Subcontractor to this prime · 1 sub-award · latest Feb 16, 2024

  • Federal Emergency Management Agency
  • “ADD-ON PROJECT 22-1155: TRANSFORMING THE EMI”

• UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  UEI MKAGLD59JRL1

  $2.2M

  Subcontracted by this company · 1 sub-award · latest Aug 22, 2024

  • National Institutes of Health
  • “MAIN CONTRACT AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF JOANNE FLYNN WILL PERFORM WORK UNDER PROJECT 1, “PROTECTION FROM INFECTION AFTER IV BCG VACCINATION,” AND PROJECT 2, “NATURAL CONTROL OF MTB INFECTION IN NHPS”; AND ALSO WORK WITH THE LABORATORY OF JOSHUA MATTILA TO EVALUATE RNASCOPE LABELLING OF INFECTED TISSUES. SPECIFICALLY, DR. FLYNN WILL: • AS CO-PI, PROVIDE SCIENTIFIC LEADERSHIP FOR THE OVERALL CONTRACT WITH DRS. FORTUNE AND BOOM. • AS LEADER FOR PROJECT 1, DESIGN, IMPLEMENT, AND OVERSEE THE NONHUMAN PRIMATE (NHP) VACCINE STUDIES, OF SIV CO-INFECTION ON IV-BCG ELICITED IMMUNITY. WORK WILL ALSO ASSESS THE PROTECTIVE SIGNALS ASSOCIATED WITH A SUBUNIT VACCINE, TB-MAPS, IN COMBINATION WITH INTRADERMAL BCG VACCINATION. • AS LEADER FOR PROJECT 2, DESIGN, IMPLEMENT, AND OVERSEE THE NONHUMAN PRIMATE (NHP) STUDIES OF CONCOMITANT IMMUNITY (INCLUDING HETEROLOGOUS CHALLENGE), PROTECTION BY CD4 CELLS, AND PROTECTION BY CD8 CELLS. • PROVIDE SAMPLES FROM THE NHP STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW. • WORK WITH THE LABORATORY OF JOSHUA MATTILA TO GENERATE FIXED INFECTED CELL LINES AND NHP TISSUE THAT WILL BE USED TO EVALUATE RNASCOPE LABELLING OF MTB IN SITU. • MEET THE DELIVERABLES SET FORTH IN THE IMPACTB STATEMENT OF WORK, AS LISTED BELOW. SAMPLES. WE ANTICIPATE THAT SAMPLES WILL BE PROVIDED TO THE FOLLOWING IMPACTB COLLABORATORS, SUBJECT TO CHANGE AS THE SCIENTIFIC PROGRAM DICTATES: 1. SAMUEL BEHAR, UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL: BAL, BLOOD, BONE MARROW FOR TCR IDENTIFICATION 2. ALEX SHALEK, RAGON INSTITUTE: GRANULOMA ARRAYS FOR SCRNASEQ 3. RYAN MCNAMARA, RAGON INSTITUTE: BAL, GRANULOMAS, LUNG HOMOGENATE SUPERNATANTS FOR SYSTEMS SEROLOGY 4. SARAH FORTUNE, HARVARD T.H. CHAN SCHOOL: BAL, GRANULOMAS, LUNG, LYMPH NODES FOR BARCODES AND CEQ; ALSO BAL, BLOOD FOR INNATE MECHANISM ASSAYS 5. BRYAN BRYSON, M”
• THE GENERAL HOSPITAL CORPORATION

  UEI FLJ7DQKLL226

  $2.1M

  Subcontracted by this company · 2 sub-awards · latest Mar 5, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) DESCRIPTION: AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. SPECIFICALLY, SUBRECIPIENT WILL: €¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY. AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.”
  • “RESEARCH - BASE FUNDING AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING. SPECIFICALLY, SUBRECIPIENT WILL: €¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. €¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND HOSTING TRAINEES FROM COLLABORATING LABS. AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING. SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL: €¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.”
• UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

  UEI MQE2JHHJW9Q8 · not in the directory yet

  $1.4M

  Subcontracted by this company · 2 sub-awards · latest Aug 13, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS CUTTING PROFILING TECHNOLOGY: MECHANISTIC STUDIES IN SMALL ANIMAL MODELS. SPECIFICALLY, SUBRECIPIENT WILL: €¢ PERFORM IMMUNOLOGICAL PROFILING AND MECHANISTIC STUDIES IN COLLABORATIVE CROSS MICE. €¢ DATA WILL BE PROVIDED TO MASSACHUSETTS INSTITUTE OF TECHNOLOGY FOR ANALYSIS, INTEGRATION, AND COMPUTATIONAL MODELING.”
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS CUTTING PROFILING TECHNOLOGY: MECHANISTIC DISSECTION OF T CELL RECEPTOR (TCR) SPECIFICITY. SPECIFICALLY, SUBRECIPIENT WILL: . IDENTIFY MYCOBACTERIAL ANTIGENS RECOGNIZED BY T CELLS FROM MTB-INFECTED NONHUMAN PRIMATES (WITH SAMPLES FROM THE UNIVERSITY OF PITTSBURGH), ANALYZE TCR DATA AND SELECT HIGH VALUE SEQUENCES, CLONE AND EXPRESS THEM, AND ULTIMATELY DETERMINE THEIR SPECIFICITY. WHEN NOVEL ANTIGENS ARE IDENTIFIED, THESE WILL BE PRODUCED RECOMBINANTLY, AND PROVIDED TO THE IMPACTB PROGRAM FOR TESTING IN HUMAN SAMPLES AND VACCINATION OF MICE.”
• CASE WESTERN RESERVE UNIVERSITY

  UEI HJMKEF7EJW69

  $1.3M

  Subcontracted by this company · 1 sub-award · latest Apr 22, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF HENRY BOOM WILL PERFORM WORK UNDER PROJECT 4, "RSTR, RESISTANCE TO IGRA+/TST+LTBL." THE PROJECT INCLUDES WORK AT CASE WESTERN RESERVE UNIVERSITY (CWRU) AS WELL AS WORK AT THE UGANDA- CWRU RESEARCH COLLABORATION (UCRC) FOREIGN PROJECT SITE, BASED IN KAMPALA, UGANDA. SPECIFICALLY, SUBRECIPIENT WILL: €¢ AS LEADER FOR PROJECT 4, CONDUCT TWO CLINICAL STUDIES THROUGH OUR UGANDA CWRU RESEARCH COLLABORATION, SPECIFICALLY (1) FOLLOW-UP AND ASSESSMENT OF LONG-TERM RESISTERS TO LTBI (RSTR) AND CONTROL SUBJECTS AND (2) BRONCHOALVEOLAR LAVAGE STUDIES OF RESISTERS. €¢ PROVIDE SAMPLES FROM THE CLINICAL STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS.”
• MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  UEI E2NYLCDML6V1

  $1.2M

  Subcontracted by this company · 1 sub-award · latest Aug 5, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING TECHNOLOGY: COMPUTATIONAL MODELING. SPECIFICALLY, SUBCONTRACTOR WILL: . LEAD THE DATA & RESOURCE MANAGEMENT FACETS OF THIS PROJECT, WHICH INCLUDE DATA STORAGE AND MANAGEMENT, AND INCLUDE MULTI-SCALE, INTEGRATIVE, AND CROSS-SPECIES COMPUTATIONAL MODELING. . WORK CLOSELY WITH THE EXPERIMENTAL INVESTIGATORS ON THIS PROJECT TO FACILITATE EASE OF DATA HANDLING AND ACCESS, AND IN CATALYZING THE ITERATIVE CYCLE OF EXPERIMENT AND MODELING INVOLVED IN EACH OF THE PROJECT AREAS.”
• UNIVERSITY OF WASHINGTON

  UEI HD1WMN6945W6 · not in the directory yet

  $1M

  Subcontracted by this company · 1 sub-award · latest Mar 7, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) DESCRIPTION: AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL LEAD AND PERFORM WORK UNDER THE PROGRAM’S CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. SPECIFICALLY, SUBRECIPIENT WILL: • HARMONIZE FLOW CYTOMETRY WORK ACROSS THE THREE CLINICAL SITES (SEATTLE, CAPE TOWN, AND LONDON). • DEVELOP, OPTIMIZE AND APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG CELLS FROM NON-HUMAN PRIMATE STUDIES IN PROJECTS 1-2. • PERFORM SINGLE-CELL RNA-SEQUENCING ON HUMAN AND NON-HUMAN PRIMATE BLOOD OR TISSUE SAMPLES RESEARCH (OPTIONS 1 AND 2) AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL LEAD AND PERFORM WORK UNDER THE PROGRAM’S CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. SPECIFICALLY, FOR THE “OPTIONAL STUDIES – CYTOF OPTION 1 AND 2” DR. SESHADRI WILL: • OPTION 1: ACCELERATE HARMONIZATION OF MASS CYTOMETRY (CYTOF) BETWEEN HUMAN AND NHP (WITH THE UNIVERSITY OF CAPE TOWN) • OPTION 2: APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG CELLS FROM NONHUMAN PRIMATE STUDIES IN PROJECT 1 (BCG-IV).”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.